Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

MDS04-85

A Phase II Randomized Trial with a Modified Dose and Schedule of Subcutaneously Administered Azacitidine and Erythropoietin versus Azacitidine Alone in Patients with Low-Risk Myelodysplastic Syndromes (Less than 11% Marrow and Peripheral Blood Blasts)

Manuscripts/Articles:

  • Sayar H, Chan RJ, Orschell CM, Chan EM, Yu Z, Hood D, Plett A, Yang Z, Hui CL, Nabinger SC, Kohlbacher KJ, West ES, Walter A, Sampson C, Wu J, Cripe LD
    Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group MDS04-85
    Leuk Res. 2011 Aug;35(8):1108-10. doi: 10.1016/j.leukres.2011.02.025. Epub 2011 Mar 21.